Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Novozymes A/S B buy RudolfL

Novozymes A/S B
Start price
€55.52
11.09.20 / 50%
Target price
€63.00
04.11.21
Performance (%)
18.70%
End price
€65.90
05.11.21
Summary
This prediction ended on 05.11.21 with a price of €65.90. The prediction had a final performance of 18.70%. Dividends of €0.71 are taken into consideration when calculating the performance. RudolfL has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Novozymes A/S B 2.079% 2.079% -0.037% 13.660%
iShares Core DAX® -0.793% 4.201% 19.951% 70.602%
iShares Nasdaq 100 -2.376% 0.857% 4.704% 103.322%
iShares Nikkei 225® -2.701% -0.147% 12.609% 44.593%
iShares S&P 500 -1.689% 1.244% 3.144% 64.741%

According to RudolfL what are the pros and cons of Novozymes A/S B for the foreseeable future?

Pros
Market Leader or Top 3
Higher EBIT margin than peer group
positive Cash Flow expected
ROE higher than 15% per year
Cons
Revenue decline/stagnation expected

Comments by RudolfL for this prediction

In the thread Novozymes A/s Nam. B diskutieren
Prediction Buy
Perf. (%) 18.70%
Target price 63.000
Change
Ends at 04.11.21

Buy mit Kursziel 63,0

RudolfL 
0
Report Share
11.09.20
In the thread Trading Novozymes A/s Nam. B
Prediction Buy
Perf. (%) 18.70%
Target price 63.000
Change
Ends at 04.11.21

Die von RudolfL gewählte maximale Laufzeit wurde überschritten

RudolfL 
0
Report Share
05.11.21

Stopped prediction by RudolfL for Novozymes A/S B

buy
Novozymes A/S B

Start price
Target price
Perf. (%)
€46.87
26.01.20
€53.00
13.08.20
5.33%
13.08.20

Market Leader or Top 3
Higher EBIT margin than peer group
positive Cash Flow expected
Revenue decline/stagnation expected
RudolfL 
26.01.20 50%